Patents Assigned to FIMECS, INC.
  • Heterocyclic compound
    Patent number: 12774287
    Abstract: It is to provide a novel heterocyclic compound which has the effect of inducing degradation of interleukin-1 receptor-associated kinase-M (IRAK-M) protein and is expected to be useful for the prevention/treatment of cancer, fibrosis, infectious diseases, etc. The present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: October 27, 2026
    Assignee: FIMECS, Inc.
    Inventors: Yusuke Tominari, Yoshihide Tomata, Kanae Gamo, Naomi Kitamoto
  • Heterocyclic compound
    Patent number: 12202829
    Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: January 21, 2025
    Assignee: FIMECS, Inc.
    Inventors: Yusuke Tominari, Yoshihide Tomata, Kanae Gamo, Naomi Kitamoto
  • HETEROCYCLIC COMPOUND
    Publication number: 20230242529
    Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.
    Type: Application
    Filed: February 16, 2023
    Publication date: August 3, 2023
    Applicant: FIMECS, Inc.
    Inventors: Yusuke TOMINARI, Yoshihide TOMATA, Kanae GAMO, Naomi KITAMOTO
  • Heterocyclic compound
    Patent number: 11639354
    Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 2, 2023
    Assignee: FIMECS, INC.
    Inventors: Yusuke Tominari, Yoshihide Tomata, Kanae Gamo, Naomi Kitamoto
  • HETEROCYCLIC COMPOUND
    Publication number: 20220402935
    Abstract: It is to provide a novel heterocyclic compound which has the effect of inducing degradation of interleukin-1 receptor-associated kinase-M (IRAK-M) protein and is expected to be useful for the prevention/treatment of cancer, fibrosis, infectious diseases, etc. The present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 31, 2020
    Publication date: December 22, 2022
    Applicant: FIMECS, INC.
    Inventors: Yusuke TOMINARI, Yoshihide TOMATA, Kanae GAMO, Naomi KITAMOTO
  • HETEROCYCLIC COMPOUND
    Publication number: 20210179614
    Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.
    Type: Application
    Filed: July 31, 2019
    Publication date: June 17, 2021
    Applicant: FIMECS, INC.
    Inventors: Yusuke TOMINARI, Yoshihide TOMATA, Kanae GAMO, Naomi KITAMOTO